Status:
COMPLETED
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C Infection
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the s...
Eligibility Criteria
Inclusion
- Read and signed the written informed consent form (ICF) after the nature of the study has been fully explained.
- All participants of childbearing potential must agree to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug.
Exclusion
- Pregnant or breastfeeding.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01813552
Start Date
February 1 2013
End Date
March 1 2013
Last Update
January 22 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.